India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/kronox-lab-sciences-ltd" target="_blank" data-smartkarma-citation="entities:46205:1" rel="noopener">Kronox Lab Sciences Ltd (KRONOX IN)</a> specializes in manufacturing over 185 high-purity specialty fine chemicals, serving needs across pharmaceutical, biotech, and nutraceutical industries globally. </li>
<li>The upcoming Dahej facility, starting Phase 1 by December 2025, aims to diversify into nutraceuticals and is projected to contribute in generating INR 300 Crores revenue by FY27.</li>
<li>
Risks include stringent global purity standards, potential product rejections, geographic concentration in Gujarat, and the 18-month-long customer approval cycles required for new certified business.</li>
</ul>



Kronox Lab Sciences Ltd (KRONOX IN) specializes in manufacturing over 185 high-purity specialty fine chemicals, serving needs across pharmaceutical, biotech, and nutraceutical industries globally. 
The upcoming Dahej facility, starting Phase 1 by December 2025, aims to diversify into nutraceuticals and is projected to contribute in generating INR 300 Crores revenue by FY27.

Risks include stringent global purity standards, potential product rejections, geographic concentration in Gujarat, and the 18-month-long customer approval cycles required for new certified business.


Kronox Lab Sciences Limited: Unit-IV as a Strategic Breakout Catalyst?

India

Kronox Lab Sciences Ltd. engages in the manufacture and sale of chemicals. Its chemicals are used in manufacturing of active pharmaceutical ingredients, biotech, scientific research and laboratory testing, nutraceuticals formulations, agrochemicals, personal care, and metal refineries. The company was founded on November 18, 2008 and is headquartered in Vadodara, India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kronox Lab Sciences (KRONOX IN)

Kronox Lab Sciences Limited: Unit-IV as a Strategic Breakout Catalyst?

Kronox Lab Sciences manufactures over 185 high-purity specialty fine chemicals. The upcoming Dahej facility aims to diversify into nutraceuticals...

Sudarshan Bhandari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Kronox Lab Sciences Limited: Unit-IV as a Strategic Breakout Catalyst?

​Kronox Lab Sciences manufactures over 185 high-purity specialty fine chemicals. The upcoming Dahej facility aims to diversify into nutraceuticals...

Sudarshan Bhandari

Kronox Lab Sciences manufactures over 185 high-purity specialty fine chemicals. The upcoming Dahej facility aims to diversify into nutraceuticals...